19th Annual Non-Dilutive Funding Summit

The 19th Non-Dilutive Funding Summit brought together hundreds of life science industry leaders with representatives from some of the leading funding agencies including ARPA-H, SEED, NINDS, NHLBI, NIMHD, NCI and more, giving attendees the opportunity to learn more in-depth about what non-dilutive funding opportunities are available and relevant for their R&D directly from the funding agencies.

Additionally, the 2023 FreeMind Elite honorees from AmplifiDx, Sapience Therapeutics, Marker Therapeutics, and Vincere Biosciences took to the stage to present about their compies research and pipelines.

This free summit is hosted by the FreeMind Group. FreeMind helps companies secure non-dilutive funding for life science R&D and wins over $100 million each year for clients. Follow us on LinkedIn or get our newsletter for news about non-dilutive funding opportunities, announcements about conferences with the best partnering, and discounts for those conferences. The 20th Non-Dilutive Funding Summit will be January 8, 2025.

“NIH Funding for Translational Neurotherapeutic Research and Development”

The National Institute of Neurological Disorders and Stroke (NINDS)

The National Institute of Neurological Disorders and Stroke (NINDS) seeks fundamental knowledge about the brain and nervous system and uses that knowledge to reduce the burden of neurological disease for all people. To that end, NINDS supports basic, translational, and clinical neuroscience research through grants-in-aid, contracts, scientific meetings, as well as through research in its own laboratories and clinics, and funds and conducts training and career development programs to increase basic, translational and clinical neuroscience expertise and ensure a vibrant, talented, and diverse work force.

Dr. Charles Cywin

Director, Small Molecule Neurotherapeutics Development, NINDS

Dr. Charles L. Cywin joined the National Institute of Neurological Disorders and Stroke (NINDS) in 2011 in the Division of Translational Research and currently serves as the Director, Small Molecule Neurotherapeutics and has responsibility for oversight for the Blueprint Neurotherapeutics Network (BPN) and the HEAL Pain Therapeutics Development Program (PTDP). He provides project leadership and coordination for a portfolio of neuroscience drug discovery projects ranging from early discovery to Phase I trials as well as managing a suite of contracts to provide CRO and subject matter expertise to the drug discovery teams in these programs. Prior to joining NIH he spent 17 years at Boehringer Ingelheim Pharmaceuticals where he was Director, Medicinal Chemistry and was responsible for Hit to Lead and Lead Optimization programs focused on clinical candidate selection in a number of therapeutic areas. He created the lead discovery team, the parallel synthesis group and led the efforts to identify and implement new technologies, infrastructure and outsourcing in medicinal chemistry.
Dr. Cywin received his Bachelor’s degree in chemistry from Providence College, performed his doctoral training at Syracuse University focused on natural product synthesis where he was a University Fellow, and completed his postdoctoral fellowship with Professor E.J. Corey at Harvard focusing on asymmetric catalysis.